E/M Coding Alert - 2003 Issue 17
Fraud & Abuse: DRUGMAKERS' FRAUD SETTLEMENTS BIGGEST EVER FOR MEDICAID
Subscribe or sign in to view the full article.
Article Overview
This article reviews a major fraud-and-abuse settlement involving pharmaceutical manufacturers and Medicaid pricing practices. It covers the government’s recovery, the companies involved, the general nature of the allegations, the role of a whistleblower, and the broader compliance and reporting issues that made the case significant. It is most relevant to readers following healthcare fraud, pharmaceutical compliance, and Medicaid reimbursement oversight.
Why This Topic Matters
The piece highlights a high-profile enforcement action that affected federal and state Medicaid programs and drew attention to drug pricing disclosures, rebate obligations, and whistleblower-driven investigations.
What You Will Learn
- How a major Medicaid fraud settlement was structured at a high level
- Which industry and government compliance issues the case involved
- Why the whistleblower’s role was significant
- How drug pricing and reporting practices can trigger enforcement scrutiny
Who Should Read This
- Medical coders
- Compliance professionals
- Healthcare auditors
- Fraud and abuse investigators
- Pharmacy and pharmaceutical industry readers
- Revenue cycle professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com